Can a 10-day antiviral course protect kidney transplant patients from severe COVID?
NCT ID NCT07197164
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the antiviral drug remdesivir for 10 days can prevent severe COVID-19 in kidney transplant recipients who have mild or no symptoms. About 15 adults will receive the drug starting just before their transplant. The goal is to see if this approach allows safe transplantation without delay and reduces the risk of serious illness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Hospital Universitari Germans Trias i Pujol
RECRUITINGBadalona, Barcelona, 08916, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?